SEC Comment Letter for AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Sep 1, 2011
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Sept. 1, 2011 · CIK: 0000946644 · Accession: 0000000000-11-052627
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-13441
Letter
September 1, 2011 Via E-mail Charles T. Bernhardt, CPA Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Blvd., Suite 660 Philadelphia, PA 19103 Re: Hemispherx Biopharma, Inc. Preliminary Schedule 14A Filed August 22, 2011 File No. 001-13441
Dear Mr. Bernhardt: We have completed our review of your f iling. We remind you that our comment or changes to disclosure in response to our co mment do not foreclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Jeffrey Riedler
Jeffrey Riedler Assistant Director
cc: Via E-mail
Richard Feiner, Esq. Of Counsel Silverman Sclar Shin & Byrne PLLC 381 Park Avenue South New York, NY 10016
Show Raw Text
September 1, 2011 Via E-mail Charles T. Bernhardt, CPA Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Blvd., Suite 660 Philadelphia, PA 19103 Re: Hemispherx Biopharma, Inc. Preliminary Schedule 14A Filed August 22, 2011 File No. 001-13441 Dear Mr. Bernhardt: We have completed our review of your f iling. We remind you that our comment or changes to disclosure in response to our co mment do not foreclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director cc: Via E-mail Richard Feiner, Esq. Of Counsel Silverman Sclar Shin & Byrne PLLC 381 Park Avenue South New York, NY 10016